Cited by 157Diabetes, Cardiovascular Risks, and LipoproteinsHeart rate and cardiovascular healthNitric Oxide and Endothelin Effects

Effects of Metformin on Microvascular Function and Exercise Tolerance in Women With Angina and Normal Coronary Arteries

Open access
Jadhav, Sachin, Ferrell, William, Greer, Ian A., Petrie, John R., Cobbe, Stuart M., Sattar, Naveed·2006·Journal of the American College of Cardiology

Abstract

Objectives This study sought to determine whether metformin improves vascular function or myocardial ischemia in nondiabetic subjects.Background Metformin prevents diabetes and may reduce coronary events in patients with diabetes, but effects on microvascular function and angina are not clear.Methods We conducted an 8-week double-blind, randomized, placebo-controlled study of metformin 500 mg twice a day in 33 nondiabetic women with a prior history of normal coronary angiography but two consecutive positive (ST-segment depression > or =1 mm) exercise tolerance tests. All parameters were measured at baseline and at 8 weeks, together with an in vivo assessment of forearm (skin) microvascular function using laser Doppler imaging combined with iontophoresis.Results In comparison with placebo (n = 17), metformin recipients (n = 16) showed significant reductions in weight and in homeostatic model assessment for insulin resistance (p < 0.05, intention to treat). Endothelium-dependent microvascular responses improved significantly with metformin (2-way repeated analysis of variance, p = 0.0003), but responses with placebo were unchanged (p = 0.50). A comparison of change in acetylcholine responses between metformin and placebo recipients was significant, whether analyzed by a 2-way analysis of variance (p < 0.0001) or change in area under curves (mean change +392 perfusion units, 95% confidence interval [CI] 20 to 764). Endothelium-independent responses were not altered. Maximal ST-segment depression (-0.84 mm, 95% CI -1.49 to -0.20, p = 0.013), Duke score (6.1 U, 95% CI 1.8 to 10.5, p = 0.008), and chest pain incidence (-0.11 episodes/day, 95% CI -0.22 to 0.00, p = 0.056) improved in metformin relative to placebo recipients.Conclusions Metformin may improve vascular function and decrease myocardial ischemia in nondiabetic women with chest pain and angiographically normal coronary arteries. Larger controlled trials of longer duration are warranted.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2006.04.088

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In non-diabetic subjects with normal coronary arteriography but two consecutive positive exercise tolerance tests, an 8-week period on metformin improved maximal ST-segment depression, Duke score, and chest pain incidence compared with placebo.

    “In non-diabetic subjects with normal coronary arteriography but also with two consecutive positive (ST depression > 1 mm) exercise tolerance test, an 8-week period on metformin improved maximal ST-segment depression, Duke score, and chest pain incidence compared with placebo [76].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jadhav, S., Ferrell, W., Greer, I. A., Petrie, J. R., Cobbe, S. M., & Sattar, N.
Affiliations
  • Glasgow Royal Infirmary (GB)
  • Ninewells Hospital (GB)
Corresponding author
Sattar, Naveed
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2006-09
Volume
48
Issue
5
Pages
956-963
ISSN
0735-1097 (ISSN-L)
OpenAlex
W1538751400
Cited by
157
References
38
Citations by year
2026: 6 · 2025: 12 · 2024: 6 · 2023: 15 · 2022: 13 · 2021: 8 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 10 · 2015: 8 · 2014: 4 · 2013: 8 · 2012: 5
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords
metformin, angina pectoris, microvascular function, endothelial function, exercise tolerance, myocardial ischemia, non-diabetic women, normal coronary arteries, ST-segment depression, chest pain, insulin resistance, acetylcholine response
MeSH terms
Adult, Angina Pectoris, Double-Blind Method, Electrocardiography, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Metformin, Middle Aged, Weight Loss, Exercise Tolerance, Myocardial Ischemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review